Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3,.

Business Wire • 4 hours ago

This Rare Disease Biotech Name Teases Around A Buy Point

This company develops treatments for rare genetic diseases. It partners with Biogen.

Investors Business Daily • Feb 23, 2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on February 17, 2026, it granted stock options to purchase an aggregate of 22,950 shares of common stock to fiv.

Business Wire • Feb 18, 2026

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that the first patient has been dosed in the Phase 1 OSPREY study of STK-002, an investigational medicine for the treatment of Autosomal Dominant Optic Atrophy (ADOA). ADOA is a rare genetic disease that causes progressive and irreversible vision loss in both eyes starting in the first de.

Business Wire • Feb 11, 2026

Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, F.

Business Wire • Feb 4, 2026

Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA

New Headquarters Will Support Company's Work to Deliver zorevunersen, a Potential Disease-Modifying Medicine, to Patients with Dravet Syndrome and Expansion of Research Efforts Lease is One of the Largest in Greater Boston Life Sciences Over the Past Year WALTHAM, Mass., Jan. 27, 2026 /PRNewswire/ -- Anchor Line Partners, LLC and Northwood Investors, LLC announced today that they have secured a significant long-term lease with biotechnology company Stoke Therapeutics (Nasdaq: STOK) at 245 Fifth Avenue in Waltham, Massachusetts.

PRNewsWire • Jan 27, 2026

Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity

Stoke Therapeutics' TANGO ASO platform can upregulate the functional allele, targeting haploinsufficiency diseases like Dravet and ADOA. This approach gives Zorevunersen disease-modifying features, which I believe will ultimately make it a very competitive asset for Dravet if approved. I believe Zorevunersen is the core value driver. And its Phase 3 EMPEROR plus four-year OLE data suggest durable seizure reductions.

Seeking Alpha • Jan 15, 2026

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced accelerated timelines for the completion of enrollment and a Phase 3 data readout from the EMPEROR.

Business Wire • Jan 11, 2026

Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Januar.

Business Wire • Jan 6, 2026

Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117%

Biotech leader Stoke stock is running up toward a new buy point. The company's revenue surged 117% in Q3.

Investors Business Daily • Dec 16, 2025